A palmitoylated peptide, derived from the acidic carboxyl-terminal segment of the integrin αIIb cytoplasmic domain, inhibits platelet activation

Platelets

Volumn 19, Issue 7, 2008, Pages 502-511

  Koloka, Vassiliki ^a   Christofidou, Elena D ^a   Vaxevanelis, Spyros ^a   Dimitriou, Andromaxi A ^a   Tsikaris, Vassilios ^a   Tselepis, Alexandros D ^a   Panou Pomonis, Eugenia ^a   Sakarellos Daitsiotis, Maria ^a   Tsoukatos, Demokritos C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

IIb cytoplasmic domain; IIb 3 receptor; Palmitoylated peptides; Platelet aggregation inhibitor

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE; THROMBIN;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN MOTIF; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AMINO ACID SEQUENCE; BLOOD PLATELETS; CELL MEMBRANE PERMEABILITY; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN; HUMANS; PALMITIC ACID; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROTEIN BINDING; PROTEIN KINASES;

EID: 55349137378     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100802266875     Document Type: Article

References (43)

1. Hynes RO. Integrins Bidirectional, Allosteric Signaling Machines. Cell 2002;110:673-687.
2. Shattil SJ, Kashiwagi H, Pampori N. Integrin signalling: The platelet paradigm. Blood 1998;91:2645-2657.
3. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000;275:21785-21788.
4. O'Toole TE, Katagiri Y, Faull RJ, Peter K, Tamura R, Quaranta V, Loftus JC, Shattil SJ. Ginsberg MH. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994;124:1047-1059.
5. Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 2001;86:316-323.
6. Hughes PE, Diaz-Gonzalez F, Leong L, Wu C, McDonald JA, Shattil SJ. Ginsberg MH. Breaking the integrin hinge: A defined structural constraint regulates integrin signaling. J Biol Chem 1996;271:6571-6574.
7. Lu C, Takagi J, Springer TA. Association of the membrane proximal regions of the alpha and beta subunit cytoplasmic domains constrains an integrin in the inactive state. J Biol Chem 2001;276:14642-14648.
8. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas TA, Plow EF, Qin J. A structural mechanism of integrin alpha(IIb)beta(3) "inside-out" activation as regulated by its cytoplasmic face. Cell 2002;110:587-597.
9. Haas TA, Plow EF. The cytoplasmic domain of αIIb β3: A ternary complex of the integrin α and β subunits and a divalent cation. J Biol Chem 1996;271:6017-6026.
10. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003;301:1720-1725.
11. Qin J, Vinogradova O, Plow EF. Integrin Bidirectional Signaling: A Molecular View. PLoS Biol 2004;2:726-729.
12. Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 2001;86:316-323.
13. Calderwood DA. Integrin activation. J Cell Sci 2004;117:657-666.
14. Stephens G, O'Luanaigh N, Reilly D, Harriott P, Walker B, Fitzgerald D, Moran N. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J Biol Chem 1998;273:20317-20322.
15. Ginsberg MH, Yaspan B, Forsyth J, Ulmer TS, Campbell ID, Slepak M. A membrane-distal segment of the integrin alpha IIb cytoplasmic domain regulates integrin activation. J Biol Chem 2001;276:22514-22521.
16. Haas TA, Plow EF. Development of a structural model for the cytoplasmic domain of an integrin. Protein Eng 1997;10:1395-1405.
17. Aylward K, Meade G, Ahrens I, Devocelle M, Moran N. A novel functional role for the highly conserved alpha-subunit KVGFFKR motif distinct from integrin alphaIIbbeta3 activation processes. J Thromb Haemost. 2006;4:1804-1812.
18. Vinogradova O, Haas T, Plow EF, Qin J. A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc Natl Acad Sci USA 2000;97:1450-1455.
19. Yamanouchi J, Hato T, Tamura T, Fujita S. Suppression of integrin activation by the membrane-distal sequence of the integrin alphaIIb cytoplasmic tail. Biochem J 2004;379:317-323.
20. Leisner TM, Wencel-Drake JD, Wang W, Lam SC. Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations. J Biol Chem 1999;274:12945-12949.
21. Bodansky M, Bodansky A The practice of peptide synthesis. 2nd ed., Berlin: Springer; 1994.
22. Goodman M, Felix A, Moroder L, Toniolo G, ed. Methods of organic chemistry: synthesis of peptide and peptidomimetics. Stuttgard: Thieme, 2003.
23. Martin K, Meade G, Moran N, Shields DC, Kenny D. A palmitylated peptide derived from the glycoprotein Ib beta cytoplasmic tail inhibits platelet activation. J Thromb Haemost. 2003;1:2643-2652.
24. Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparations of suspensions of washed platelets of humans. Br J Haematol 1972;22:193-204.
25. Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: Role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res 2004;63:130-138.
26. IIbβ3 in human platelet signal transduction. Biochem Pharmacol 2000;60:1069-1074.
27. Leong L, Hughes PE, Schwartz MA, Ginsberg MH, Shattil SJ. Integrin signaling: Roles for the cytoplasmic tails of alpha IIb beta 3 in the tyrosine phosphorylation of pp125FAK. J Cell Sci 1995;108:3817-3825.
28. IIbβ3. Blood 2006;107:965-972.
29. Garcia A, Shankar H, Murugappan S, Kim S, Kunapuli S. Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets. Biochem J 2007;404:299-308.
30. Lévy-Toledano S. Platelet signal transduction pathways: Could we organize them into a 'hierarchy'? Haemostasis 1999;29:4-15.
31. McNicol A, Jackson ECJ. Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem Pharmacol 2003;65:1243-1250.
32. Weljie AM, Hwang PM, Vogel HJ. Solution structures of the cytoplasmic tail complex from platelet integrin alpha IIb- and beta 3-subunits. Proc Natl Acad Sci USA 2002;99:5878-5883.
33. Shimaoka M, Takagi J, Springer TA. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 2002;31:485-516.
34. Travis MA, Humphries JD, Humphries MJ. An unraveling tale of how integrins are activated from within. Trends Pharmacol Sci 2003;24:192-197. 35. Shattil SJ, Brugge JS. Protein tyrosine phosphorylation and the adhesive functions of platelets. Curr Opin Cell Biol 1991;3:869-879.
35. Schoenwaelder SM, Jackson SP, Yuan Y, Teasdale MS, Salem HH, Mitchell CA. Tyrosine kinases regulate the cytoskeletal attachment of integrin alpha IIb beta 3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin polymers. J Biol Chem 1994;269:32479-32487.
36. Hers I, Donath J, van Willigen G, Akkerman JW. Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure. Arterioscler. Thromb Vasc Biol 1998;18:404-414.
37. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, Ginsberg MH, Calderwood DA. Talin binding to integrin beta tails: A final common step in integrin activation. Science 2003;302:103-106.
38. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J Biol Chem 1999;274:28071-28074.
39. Knezevic I, Leisner TM, Lam SC. Direct binding of the platelet integrin alphaIIbbeta3 (GPIIb-IIIa) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alphaIIb and beta3. J Biol Chem 1996;271:16416-16421.
40. Quinn MJ, Byzova TV, Qin J, Topol EF, Plow EF. Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003;23:945-952.
41. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
42. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000;36:1514-1519.
43. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUSTIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis in Myocardial Infarction. Am J Cardiol 2000;85:491-493.